clinical trial · NCT05206513
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
DyskinesiaCerebral PalsyPlaceboValbenazine
brief summary
The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.
started
Apr 15, 2022
primary completion
Oct 16, 2025
completion
Mar 31, 2026
last updated
Apr 29, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol